Focused On-demand Library for GEL complex subunit OPTI

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9BUV8

UPID:

RCAF1_HUMAN

Alternative names:

Obligate partner of TMCO1 insertase; Rab5-interacting protein; Respirasome Complex Assembly Factor 1

Alternative UPACC:

Q9BUV8; E1P5U0; O00605; Q5QPG6; Q5QPG7; Q9BT03; Q9BZU7; Q9UI05

Background:

GEL complex subunit OPTI, also known as Obligate partner of TMCO1 insertase, Rab5-interacting protein, and Respirasome Complex Assembly Factor 1, plays a crucial role in cellular processes. It is a component of the multi-pass translocon (MPT) complex, facilitating the insertion of multi-pass membrane proteins into the lipid bilayer. This protein also acts as an assembly factor for mitochondrial respiratory complexes, highlighting its importance in cellular respiration and energy production.

Therapeutic significance:

GEL complex subunit OPTI is linked to Craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development syndrome 2, a disorder with significant genetic underpinnings. Understanding the role of GEL complex subunit OPTI could open doors to potential therapeutic strategies, offering hope for targeted interventions in this and related conditions.